Esin ŞENOL, Gülsan SUCAK, Zübeyde Nur ÖZKURT, Derya KETEN TOZLU, Murat DİZBAY, Özlem Güzel TUNÇCAN

Relationship between teicoplanin use and ıncrease in minimal inhibitor concentrations of coagulase-negative staphylococci

Amaç: Hematolojik maligniteli hastaların kateter ilişkili kan dolaşım infeksiyonlarından (KİKDİ) izole edilen Koagülaz negatif stafilokok (KNS)lardaki Minimal inhibitör konsantrasyon (MİK) artışı ve teikoplanin kullanımı arasındaki ilişkiyi belirlemek amaçlanmıştır. Gereç ve Yöntemler: Bu çalışma 2006-2010 yılları arasındaki KİKDİ olan febril nötropenik hastalardan izole edilen KNS suşlarında yapılmıştır. Teikoplanin MİK düzeyleri E-test® yöntemiyle belirlenmiştir. Hastaların demografik özellikleri, altta yatan hematolojik hastalıkları, teikoplanin doz ve süreleri kaydedilmiştir. Teikoplanin gramları ve uluslararası birimleri tanımlanmış günlük doza (DDD) çevrilmiştir. Bulgular: Kateter ilişkili kan dolaşım enfeksiyonlu febril nötropenik hastalardan izole edilen toplam 72 KNS suşu incelenmiştir. En sık izole edilen KNS suşlarını Staphylococcus epidermidis 34(%47), Staphylococcus haemolyticus 30(%42)oluşturmuştur. Oksasilin direnci tüm izolatların %74ünde saptanmıştır. Hastaların 44(%61)ünde KNS suşlarının MİK değerlerinde artış saptanmıştır. Tedavi öncesi KNS suşları arasında Teikoplanin için MİK değeri 2.1±1.76 μg/ml, ve tedavi sonrası bu değer 4.4±3.89 μg/ml olarak saptanmıştır (p

Koagülaz negatif stafilokoklardaki minimal inhibitör konsantrasyon artışı ile teikoplanin kullanımı arasındaki ilişki

Aim: We aimed to determine the relationship between teicoplanin use and increased minimal inhibitor concentrations of coagulase-negative staphylococci (CNS) isolated from catheter related bloodstream infections (CRBSI) in patients with hematological malignancies. Methods: The study was performed on CNS strains isolated from CRBSI of FN patients during the period between 2006-2010. Teicoplanin MICs were determined by using the Etest method. Demographic characteristics of patients, underlying hematological diseases, the dose and course of teicoplanin were recorded. Grams and international units of teicoplanin were further converted into defined daily doses (DDD). Results: A total of 72 CNS strains causing CRBSI isolated from FN attacks of the patients were analyzed. Among them, Staphylococcus. epidermidis (47%) and Staphylococcus haemolyticus (42%) were the most frequent CNS species. Oxacillin resistance was detected in 74% of all isolates. Increase in MIC values among CNS strains were detected in 44 patients (61%). Mean MIC value for teicoplanin among CNS strains before the treatment was 2.1±1.76 μg/ml, and it was 4.4±3.89 μg/ml after the treatment (p

PDF

___

1.Bertin M, Muller A, Bertrand X, Cornette C, Thouverez M, Talon D. Relationship between glycopeptide use and decreased susceptibility to teicoplanin in isolates of coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis 2004; 23: 3759.
2. Biavasco F, Vignaroli C, Varaldo PE. Glycopeptide resistance in coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis. 2000; 19: 403-17
3. Biavasco F, Vignaroli C, Lazzarini R, Varaldo PE. Glycopeptide susceptibility profiles of Staphylococcus haemolyticus bloodstream isolates. Antimicrob Agents Chemother. 2000; 44: 3122-6.
4. Blans M, Troelstra A. Glycopeptide resistance in Staphylococcus haemolyticus during treatment with teicoplanin. Infect Control Hosp Epidemiol. 2001; 22: 263-4.
5. Natoli S, Fontana C, Favaro M, Bergamini A, Testore GP, Minelli S, et al. Characterization of coagulase-negative staphylococcal isolates from blood with reduced susceptibility to glycopeptides and therapeutic options. BMC Infect Dis. 2009; 9: 83.
6. Natsch S, Hekster YA, de Jong R, Heerdink ER, Herings RM, van der Meer JW. Application of the ATC/DDD methodology to monitor antibiotic drug use. Eur J Clin Microbiol Infect Dis 1998; 17: 2024
7. Clinical and laboratory Standards Institute: Performance Standard for Antimicrobial Susceptibility Testing. Twentieth Informational supplement. CLSI Document M100-S20, CLSI Wayne, PA (2010)
8. Gales AC, Sader HS, Ribeiro J Zoccoli C, Barth A, Pignatari AC. Antimicrobial susceptibility of gram-positive bacteria isolated in Brazilian hospitals participating in the SENTRY Program (2005-2008). Braz J Infect Dis. 2009 ; 13: 90-8.
9. Sader HS, Fritsche TR, Jones RN. Frequency of occurrence and daptomycin susceptibility rates of Gram-positive organisms causing bloodstream infections in cancer patients. J Chemother. 2008; 20: 570- 6.
10. Graninger W, Assadian O, Lagler H, Ramharter M. The role of glycopeptides in the treatment of intravascular catheter-related infections. Clin Microbiol Infect. 2002;8:310-5.
11. de Allori MC, Jure MA, Romero C, de Castillo ME. Antimicrobial resistance and production of biofilms in clinical isolates of coagulase- negative Staphylococcus strains. Biol Pharm Bull. 2006; 29: 1592-6.
12. Sieradzki K, Villari P, Tomasz A. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrob Agents Chemother. 1998; 42: 100- 7.
13. Vedel G, Leruez M, Lémann F, Hraoui E, Ratovohery D. Prevalence of Staphylococcus aureus and coagulase-negative staphylococci with decreased sensitivity to glycopeptides as assessed by determination of MICs. Eur J Clin Microbiol Infect Dis. 1990; 9: 820-2.